Evidence map›Paper›PMID 32907896›Full record

ArticleBMJ open2020

Strategies adopted by men to deal with uncertainty and anxiety when following an active surveillance/monitoring protocol for localised prostate cancer and implications for care: a longitudinal qualitative study embedded within the ProtecT trial.

Julia Wade, Jenny Donovan, Athene Lane, Michael Davis, Eleanor Walsh, David Neal, Emma Turner, Richard Martin, Chris Metcalfe, Tim Peters and 14 more

Abstract read
In one paragraph

Article in BMJ open, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Julia WadePopulation Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK julia.wade@bristol.ac.uk.ORCID 0000-0001-6486-6477
Jenny DonovanPopulation Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
Athene LanePopulation Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
Michael DavisPopulation Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
Eleanor WalshPopulation Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
David NealNuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.
Emma TurnerPopulation Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
Richard MartinPopulation Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
Chris MetcalfePopulation Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
Tim PetersPopulation Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
Freddie HamdyNuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.
Roger KockelberghDepartment of Urology, University Hospitals of Leicester NHS Trust, Leicester, UK.
James CattoDepartment of Oncology and Metabolism, University of Sheffield Medical School, Sheffield, UK.
Alan PaulDepartment of Urology, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
Peter HoldingNuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.
Derek RosarioDepartment of Oncology and Metabolism, University of Sheffield, Sheffield, UK.
Howard KynastonSchool of Medicine, Cardiff University, Cardiff, UK.
Edward RoweDepartment of Urology, North Bristol NHS Trust, Bristol, UK.
Owen HughesDepartment of Urology, Cardiff and Vale University Health Board, Cardiff, UK.
Prasad BollinaDepartment of Urology, NHS Lothian, Edinburgh, UK.
David GillattFaculty of Medicine, Health and Human Science, Macquarie University, Sydney, New South Wales, Australia.
Alan DohertyDepartment of Urology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
Vincent J GnanapragasamDepartment of Surgery, University of Cambridge, Cambridge, UK.
Edgar PaezDepartment of Urology, Newcastle Upon Tyne Hospitals NHS Trust, Newcastle Upon Tyne, UK.

Funding

Cancer Research UK 15064Cancer Research UK 24432
6 · The paper itself

Abstract

objectivesActive surveillance (AS) enables men with low risk, localised prostate cancer (PCa) to avoid radical treatment unless progression occurs; lack of reliable AS protocols to determine progression leaves uncertainties for men and clinicians. This study investigated men's strategies for coping with the uncertainties of active monitoring (AM, a surveillance strategy within the Prostate testing for cancer and Treatment, ProtecT trial) over the longer term and implications for optimising supportive care.

designLongitudinal serial in-depth qualitative interviews every 2-3 years for a median 7 (range 6-14) years following diagnosis.

settingFour centres within the UK Protect trial.

participantsPurposive sample of 20 men with localised PCa: median age at diagnosis 64 years (range 52-68); 15 (75%) had low-risk PCa; 12 randomly allocated to, 8 choosing AM. Eleven men continued with AM throughout the study period (median 7 years). Nine received radical treatment after a median 4 years (range 0.8-13.8 years).

interventionAM: 3-monthly serum prostate-specific antigen (PSA)-level assessment (year 1), 6-12 monthly thereafter; increase in PSA ≥50% during previous 12 months or patient/clinician concern triggered review. MAIN OUTCOMES: Thematic analysis of 73 interviews identified strategies to accommodate uncertainty and anxiety of living with untreated cancer; implications for patient care.

resultsMen sought clarity, control or reassurance, with contextual factors mediating individual responses. Trust in the clinical team was critical for men in balancing anxiety and facilitating successful management change/continued monitoring. Only men from ProtecT were included; men outside ProtecT may have different experiences.

conclusionMen looked to clinicians for clarity, control and reassurance. Where provided, men felt comfortable continuing AM or having radical treatments when indicated. Clinicians build patient trust by clearly describing uncertainties, allowing patients control wherever possible and being aware of how context influences individual responses. Insights indicate need for supportive services to build trust and patient engagement over the long term. TRIAL REGISTRATION NUMBER: ISRCTN20141297; Pre-results.

Indexed as

Prostatic NeoplasmsWatchful WaitingAgedAnxietyHumansMaleMiddle AgedProstate-Specific AntigenUncertaintyProstate-Specific Antigenprostate diseasequalitative researchurological tumours

Identifiers

PMID32907896
PMCPMC7482454

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.